Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Daratumumab (Darzalex) is indicated for the treatment of adults with multiple myeloma, both newly diagnosed and relapsed or refractory. It may be used alone or in combination with other drugs such as lenalidomide, dexamethasone, bortezomib, melphalan, prednisone, thalidomide, and carfilzomib.
• Information was derived from 23 systematic reviews/meta-analyses focusing on daratumumab's safety and efficacy in treating multiple myeloma across different patient populations.
• Compared to regimens like lenalidomide/bortezomib/dexamethasone (RVD), daratumumab shows superior efficacy, especially in terms of stringent complete remission rates and progression-free survival among transplant-ineligible newly diagnosed patients.
• For elderly patients with relapsed/refractory multiple myeloma, adding daratumumab to their therapy has shown high effectiveness, particularly when combined with lenalidomide and dexamethasone. This combination has also demonstrated acceptable safety levels despite an increase in certain adverse events such as thrombocytopenia and neutropenia.
• Various subgroups, including elderly patients, standard-risk cytogenetics patients, high-risk cytogenetics patients, those ineligible for transplant, or those who are refractory to lenalidomide-based treatments, have all benefited significantly from daratumumab-containing regimens.
• Patients suffering from hepatic disease may potentially benefit from using this drug without significant differences in its efficacy based on hepatic function subgroup considerations.
• Daratumumab combinations are frequently cited as most effective compared to other treatments, specifically DaraLenDex & DVMP regimens, which provide superior progression-free survival and overall survival benefits, vastly for relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma respectively.
• The use of daratumumab-containing regimens, especially when combined with lenalidomide-carfilzomib or daratumumab alone, has shown significant efficacy over placebo in extending progression-free survival post-induction therapy for newly diagnosed multiple myeloma.